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BACKGROUND: The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared
with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or second-line chemotherapy in patients with metastatic
colorectal cancer.
METHODS: On the basis of NO16966 and NO16967 trials, mean costs and effectiveness were calculated from patient-level data. Until
the disease progressed, the mean costs were calculated from the perspective of health-care payers in Japan. We estimated mean
quality-adjusted progression-free survival days (QAPFSD), considering adverse events and patient preference for chemotherapy
regimens. Utility scores were obtained by a web-based survey from general people, randomly sampled from a large panel adjusted for
sex and age.
RESULTS: Incremental effectiveness of XELOX as first-line and second-line chemotherapy for colorectal cancer patients was significantly
greater. By use of XELOX, patients gained 10.5 QAPFSD from first-line treatment or 11.3 QAPFSD from second-line treatment.
Capecitabine plus oxaliplatin (XELOX) was also proven to significantly reduce treatment costs by h3000 (JPY 360000) and h2300
(JPY 270000) for first-line and second-line treatment, respectively. In health-care settings in the United Kingdom, XELOX decreased
medical costs for National Health Service by d7600 and d3900 for patients who received first-line and second-line treatment,
respectively.
CONCLUSION: Capecitabine plus oxaliplatin (XELOX) as first-line and second-line chemotherapy was ‘dominant’. In terms of
effectiveness and cost, XELOX was superior to FOLFOX4.
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A total of 40000 people die each year from colorectal cancer, which
is the third leading cause of death due to malignant neoplasms
after lung cancer and stomach cancer (Ministry of Health, Labour
and Welfare, 2007) in Japan. Moreover, the age-adjusted incidence
rate of colorectal cancer is approximately 40 per 100000 people,
representing the second highest incidence rate for a malignant
neoplasm after stomach cancer (Center for Cancer Control and
Information Services, 2007).
Significant progress in chemotherapy of metastatic colorectal
cancer (MCRC) has been made in recent years (Kelly and
Goldberg, 2005; Meyerhardt and Mayer, 2005). Until approxi-
mately the year 2000, 5-fluorouracil (5-FU) plus leucovorin (LV)
was the standard regimen used in most countries, but oxaliplatin-
or irinotecan-containing regimens were developed rapidly and are
now widely administered to many MCRC patients. As a result,
median overall survival (OS) of patients with MCRC has improved
steadily over this decade (Meyerhardt and Mayer, 2005). As
monoclonal antibody drugs, such as bevacizumab or cetuximab,
are administered to many of them in addition to chemotherapy,
the current challenge is to maintain good quality of life (QOL) and
prolong survival for MCRC patients who receive chemotherapy.
Oxaliplatin regimens, FOLFOX4 (de Gramont et al, 2000) or
FOLFOX6 (Tournigand et al, 2004), are the most frequently used
chemotherapies for MCRC. Unfortunately, these two regimens
frequently yield oxaliplatin-caused adverse events (AEs), especially
neuropathy, which greatly influences QOL. Furthermore, patients
receiving a FOLFOX regimen must undergo a 2-day continuous
infusion of 5-FU every 2 weeks. Even without AEs from the
chemotherapy, the 2-day continuous infusion may decrease patient
QOL. To avoid continuous infusion, as is necessary for 5-FU
administration, the use of oral fluorinated pyrimidine drugs, such
as capecitabine, has recently increased.
Capecitabine belongs to the fluorinated pyrimidine class of
anticancer drugs. It is metabolised in the body and eventually
converted into FU within tumour tissue, where it shows
antitumour activity (Miwa et al, 1998). Because the enzyme
(thymidine phosphorylase) responsible for the last conversion step
is more concentrated in tumour tissue than in normal tissues, FU
levels in tumour tissue are selectively increased (Schuller et al,
2000). Thus, capecitabine offers an improved tolerability profile
compared with FU/LV with respect to some systemic AEs (Cassidy
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set al, 2002). Also, as capecitabine is given orally, it avoids the need
for intravenous drug preparation and administration and asso-
ciated visits to the clinic. Patient preference data also suggest that
patients generally prefer oral over intravenous therapy (Twelves
et al, 2006).
Capecitabine plus oxaliplatin (XELOX) (Hochster et al, 2006;
Diaz-Rubio et al, 2007; Porschen et al, 2007; Rothenberg et al,
2008; Saltz et al, 2008) is an improved regimen which includes
capecitabine but does not require 5-FU infusion. NO16966 (Saltz
et al, 2008) and NO16967 (Rothenberg et al, 2008) clinical
trials, which compared XELOX and FOLFAX4, demonstrated
non-inferiority of XELOX as first-line (Saltz et al, 2008) and
second-line chemotherapy (Rothenberg et al, 2008), based on
progression-free survival (PFS) (hazard ratio (HR)¼1.05; 97.5%
confidence interval (CI)¼0.94–1.18 in the NO16966 trial)
(HR¼1.03; 95% CI¼0.87–1.24 in the NO16967 trial). However,
it is unknown which regimen is more cost-effective.
In many developed countries, increased medical costs represent
a major issue. Making decisions about health-care interventions
that consider costs, in addition to efficacy and safety, has become
increasingly important. Our objective was to compare not only
costs but also quality-adjusted life-years (QALY), that is, whether
people clearly prefer oral chemotherapy to intravenous chemo-
therapy considering both gained life year and utility of
chemotherapy. This study measured original utility scores, and
people’s preference for oral chemotherapy was incorporated into
QALY calculations and thus reflected in the analysis. Thus, we
investigated the cost-effectiveness of XELOX in comparison with
FOLFOX4 from the perspective of health-care payers.
MATERIALS AND METHODS
Our economic evaluation of XELOX was performed retrospec-
tively, based on patient-level data from two multinational
randomised clinical trials, NO16966 and NO16967.
Patients receiving chemotherapy regimens
In the NO16966 trial of first-line chemotherapy, MCRC patients
were randomised to four groups: XELOX (i.v. infusion of
oxaliplatin at 130mgm
 2 on day 1 every 3 weeks, oral capecitabine
at 1000mgm
 2 b.i.d. for 2 weeks followed by 1 week without
treatment); XELOXþbevacizumab (BV) (i.v. BV at 7.5mgkg
 1);
FOLFOX4 (i.v. infusion of oxaliplatin at 85mgm
 2 on day 1 of a
2-week cycle, i.v. infusion of LV at 200mgm
 2 on days 1 and 2, i.v.
5-FU delivered as 400mgm
 2 bolus injection on days 1 and 2
followed by a continuous infusion at 600mgm
 2 over a period of
22h on days 1 and 2); and FOLFOX4þBV (i.v. BV at 5mgkg
 1).
Two BV groups in the NO16966 trial were excluded from the
current analysis. In the NO16967 trial of second-line chemother-
apy, patients were randomised to XELOX or FOLFOX4 treatment,
as there were no BV groups in NO16967 trial.
Economic evaluation
We performed a cost-effectiveness study of XELOX as first-line
and second-line chemotherapy, as compared with FOLFOX4, for
MCRC patients. The cost-effectiveness of XELOX for first-line
therapy was assessed based on data from the NO16966 trial,
whereas the cost-effectiveness of second-line treatment with
XELOX was evaluated based on data from the NO16967 trial.
Because the prognoses for both XELOX and FOLFOX4
treatments of MCRC were the same, incremental effectiveness
was estimated by the difference in quality-adjusted progression-
free survival days (QAPFSD). Hazard ratio of OS was 0.98 (97.5%
CI¼0.82–1.17) in the NO16966 trial and 1.03 (95% CI¼0.87–
1.23) in the NO16967 trial. Therefore, the difference in QAPFSD/
365 days was thought to be equal to the difference in QALY. As a
secondary analysis we also calculated the difference in progres-
sion-free survival days (PFSD). For the same reason, this can be
regarded as the difference of life years.
Incremental cost was calculated by the difference in total costs
during the period of PFS. Because the use and duration of post-
treatment chemotherapy of XELOX- or FOLFOX4-treated patients
was not considered to be different, the costs during PFS were
regarded as the incremental total costs.
In this cost-effective analysis, the perspective was that of health-
care payers, which included only direct medical cost, not indirect
cost (e.g., work loss). Neither costs nor outcome were discounted
because of the short time horizon of the trials.
Patients
For the analysis set of patients, we used the intent-to-treat (ITT)
population, and patients who did not receive even one dose of
predetermined protocol chemotherapy were excluded. From the
NO16966 trial, the ITT population used in our analysis was XELOX
(n¼655) and FOLFOX4 (n¼649); from the NO16967 trial, the ITT
population used in our analysis was XELOX (n¼311) and
FOLFOX4 (n¼308). Of the ITT population from the two trials
used in our analysis, baseline characteristics of the patients are
shown in Table 1.
Utility scores and outcome measurement
Using time tradeoff (TTO) methods, utility scores for both
chemotherapy regimens and seven grade 3/4 AEs were assessed
through an online survey of the general population. For cost-
effectiveness analysis, the use of utility scores from the general
populous rather than that from the patient population is
recommended (Gold et al, 1996). The seven AEs of febrile
neutropenia, nausea/vomiting, diarrhoea, hand–foot syndrome,
fatigue, peripheral neuropathy, and stomatitis due to chemo-
therapy were chosen because they were the main chemotherapy-
related AEs observed in the NO16966 trial.
We developed first draft of health states designed to describe an
MCRC patient based on interviews with experts, literature review
(Lloyd et al, 2006), NCI Common Terminology Criteria for
Adverse Events (CTCAE), and health-related quality of life
(HRQOL) questionnaires (especially, the EQ-5D questionnaire).
First draft of health states were reviewed independently by two
experienced oncologists and two oncologic clinical research
Table 1 Baseline patient characteristics
NO16966 trial NO16967 trial
Chemotherapy regimen FOLFOX4 XELOX FOLFOX4 XELOX
Patient characteristics
Number of patients 649 655 308 311
Male gender (%) 57.9 59.8 60.7 62.1
Race
Caucasian (%) 81.7 82.2 81.8 81.7
Black (%) 1.7 2.0 1.9 3.2
Other (%) 16.6 15.7 16.2 15.1
Age (years) 59.7 59.7 59.7 60.7
Weight (kg) 72.6 72.6 77.5 75.5
ECOG performance
0 (%) 56.1 55.0 46.4 48.2
1 (%) 43.8 45.0 46.8 44.3
2 (%) — — 6.8 7.4
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scoordinators. After we received their comments, we improved
descriptions of health states and made second draft accordingly.
Following review of the second draft on health states by other
clinical research coordinators, we carefully modified the descrip-
tions to achieve a completed document on final health states
(Figure 1).
Respondents were asked to read about one health state and
imagine that they currently live in that state of health.
Approximately 180 survey responses of each health state were
collected from the largest Internet-based panel in Japan. Popula-
tion size of the field panel (INTAGE Interactive Inc., Tokyo, Japan)
is 760000 people. Respondents were randomly sampled, stratified
by gender and age. The statistical analysis method utilised was
described earlier in a report by Lloyd et al (2006).
Using measured utility scores, we calculated the mean QAPFSD
based on PFS and onset date and end date of grade 3/4 AEs. Mean
QAPFSD of each group was estimated by nonparametric, direct
methods for patient data (Willan and Briggs, 2007). The CI for
mean QAPFSD was constructed by the bootstrap method (Efron
and Tibshirani, 1993).
Medical resource use and costs
Consumption of medical resources on anticancer drugs and
premedication drugs before oxaliplatin administration was esti-
mated by patient dose of medications. Outpatient chemotherapy
fee (including fees for outpatient chemotherapeutic medications,
fee for blood test, fee for diagnostic imaging, and pharmacy fee)
was added to medical costs, following the schedule determined by
the chemotherapy protocol. Unit costs were calculated for the year
2007 in Japan, based on the reimbursement schedule of social
insurance in 2006 (Laboratory, 2006) and the drug tariff in 2007
(Jiho, 2007).
Because marketing of generic levo leucovorin (l-LV) began in
2007, we calculated the cost of FOLFOX4 using both the price of
branded and generic l-LV. Censored data were considered to
calculate the mean cost per patient, according to the method of Lin
et al (1997). Also, CIs for mean cost were constructed by the
bootstrap method.
Costs of medication for management of treatment-related AEs
were also considered. Costs of hospitalisation for AEs were not
included in the base-case analysis, as no data on actual resource
consumption due to hospitalisation for AEs were available. Impact
of costs on the current analysis was determined by sensitivity
analyses.
All costs expressed in Japanese Yen (f) were converted to Euros
(h), using an exchange rate of f100¼h120.
Sensitivity analyses
Sensitivity analysis was used to handle parameter uncertainty. It is
possible that differences exist in chemotherapy drug dosage
administered to Euro-American and Japanese patients. Japanese
individuals generally weigh less and have a smaller body surface
area relative to Euro-Americans. As such, a sensitivity analysis was
performed for dosage. Notably, unadjusted dosage was used in the
base-case analysis. Impact of hospitalisation cost for AEs was also
analysed because patient-level data were unavailable. Uncertainty
of the incremental cost-effectiveness ratio was evaluated, based on
the bootstrap method (in which bootstrap resampling was repeated
10000 times). In addition, we calculated medical costs for National
Health Service (NHS) in the UK health-care setting. This value
incorporated anticancer drug costs (Pandor et al, 2006; Joint
Formulary Committee, 2007), administration costs (d109 per
cycle), infusion pump costs (d62 per cycle), pharmacy costs (d38
per i.v.), hospital admission (d258 per day), clinician consultations
(d80 per cycle), and cost of diagnostic tests (d65 per chemo-
therapy) (Tappenden et al, 2007).
RESULTS
Effectiveness
Table 2 displays estimated utility scores for AEs, chemotherapy
regimens without AEs, and the 95% CIs. As a chemotherapy
regimen for the general population, XELOX was generally
preferred over FOLFOX4. Adverse event decreased utility scores
by about 0.1–0.2. These utility scores were used to calculate mean
QAPFSD of each patient group.
Results of the cost-effectiveness analysis are displayed in Table 3.
Incremental effectiveness of XELOX was significantly larger than 0
for both first-line and second-line therapy. Incremental effective-
ness of first-line XELOX for MCRC patients was 10.5 QAPFSD,
whereas incremental effectiveness of second-line XELOX for
MCRC patients was 11.3 QAPFSD. The difference in PFSD was
 9.3 PFSD for first-line MCRC patients and 2.2 PFSD for second-
line MCRC patients. The PFSD difference between XELOX and
FOLFOX4 was not statistically significant.
Costs
Capecitabine plus oxaliplatin (XELOX) was proven to significantly
reduce treatment costs by h3000 (JPY 360000) in first-line
treatment and h2300 (JPY 270000) in second-line treatment, as
compared with FOLFOX4 involving branded l-LV. Even if the
comparator regimen was changed to FOLFOX4 involving generic
l-LV, XELOX decreased treatment costs by h1800 (JPY 220000) in
first-line therapy and h1500 (JPY 180000) in second-line therapy.
• Although you have a life-threatening illness, your symptoms are 
currently stable. You are receiving the following treatment 
regimen:
 (in the case of FOLFOX) (Once every 2 weeks, you go to the 
hospital outpatient clinic for 2 consecutive days to receive an 
intravenous drip. After returning home on those 2 days, you also 
inject medication into your body using a pump. although you are 
injecting the medication, there are no major limitations on your 
daily life, but you need to be careful that the needle does not come 
out. After the 2 days, you remove the needle on your own.)
(in the case of XELOX) (Once every 3 weeks, you receive an 
intravenous drip at the hospital’ s outpatient clinic. After going to 
the hospital, you continue to take oral medication twice every day 
for 2 weeks.)
• You do not experience any major difficulties in performing daily 
tasks, such as doing laundry, changing your clothes, or washing 
your face. But you find that you tire more quickly when you go out 
or go shopping than you did when you were healthy, and these 
activities require more effort than they did when you were healthy. 
You do not have the same amount of freedom to engage in your 
work and leisure activities than you did when you were healthy.
• At times you feel pain, but you are able to control it using 
medication.
• If the illness progresses in the future, it will not be possible to 
treat it. As a result, you feel anxiety about whether the illness will 
advance, and at times you feel depressed.
Figure 1 The health state describing an MCRC patient receiving
FOLFOX or XELOX.
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sDetailed costs are shown in Table 4. Cost of chemotherapy was
the major component in both groups analysed. Difference in
chemotherapy costs and outpatient chemotherapy fee is the factor
that had the most influence on the incremental costs of XELOX.
Cost-effectiveness
Both first-line and second-line treatments were proven to be
‘dominant’ (Table 3). These results mean that costs of XELOX were
lower, and more QALY could be gained by use of XELOX.
Sensitivity analysis
Lower doses of XELOX resulted in lower incremental costs of
XELOX. If the dose of first-line chemotherapy was reduced by
90%, costs could be reduced by h3300 (JPY 400000), as compared
with FOLFOX4 involving branded l-LV; or by h2300 (JPY 270000),
as compared with FOLFOX4 involving generic l-LV. If the dose of
second-line chemotherapy was reduced by 90%, costs could be
reduced by h3800 (JPY 450000), as compared with FOLFOX
involving branded l-LV; or by h2800 (JPY 340000), as compared
with FOLFOX4 involving generic l-LV.
The mean length of hospitalisation per patient was 1.14 days
(XELOX) and 0.77 days (FOLFOX4) in the NO16966 trial
(Scheithauer et al, 2007). No data were available on actual resource
consumption. Even if we assumed that all patients were treated in
an intensive care unit, resulting in a daily cost of h730 (JPY 87600)
per day), the difference in cost was h270 (JPY 32000). Thus, the
difference in length and type of stay had minimal, if any, influence
on total costs. More than 95% resampling data on incremental
effectiveness and costs were distributed in the ‘dominant’
quadrant, which was shown in Figure 2.
In the UK health-care setting, costs of FOLFOX4 and XELOX as
first-line therapy were estimated to be d23600 (d14000;
chemotherapy drug costs) and d16100 (d12300; chemotherapy
drug costs), respectively. Capecitabine plus oxaliplatin decreased
treatment costs by d7600. In second-line therapy, costs of
FOLFOX4 were d13600 (d8 6 0 0 ;c h e m o t h e r a p yd r u gc o s t s ) ,w h e r e a s
XELOX cost d9700 (d7600; chemotherapy drug costs). The difference
in cost was estimated to be d3900. In the UK health-care setting,
XELOX was also superior to FOLFOX4 with regard to cost.
Budget impact
Our findings have important implications for oncology expendi-
tures. An estimated 40000 patients are newly diagnosed with
MCRC in Japan each year. Assuming that use of XELOX decreased
the medical costs for an MCRC patient by h3000 (JPY 360000) and
FOLFOX4 is administered to at least one-fourth or half of newly
diagnosed MCRC patients, an annual savings of approximately h30
million (JPY 3.6 billion) or h60 million (JPY 7.2 billion) could be
possible in Japan. In the United Kingdom, the number of patients
is estimated to be 12665 (Hind et al, 2008). On the basis of our
assumption that first-line XELOX decreased medical costs for NHS
by d7600, XELOX helps to reduce the total budget by a maximum
of d96 million.
Table 3 Results of the cost-effectiveness analysis
(a) Cost
First-line therapy Second-line therapy
Chemotherapy regimen Estimated cost (h) 95% CI Estimated cost (h) 95% CI
(1) XELOX 18300 17900–18700 12600 12200–13100
(2) FOLFOX (branded l-LV) 21300 20800–21800 14900 14300–15500
(3) FOLFOX (generic l-LV) 20200 19700–20600 14100 13600–14700
(1)–(2)  3000  3600 to 2400  2300  1600 to 3000
(1)–(3)  1900  2500 to 1200  1500  2200 to 800
(b) Effectiveness (QAPFSD)
First-line therapy Second-line therapy
Chemotherapy regimen Estimated Effectiveness (QAPFSD) 95% CI Estimated Effectiveness (QAPFSD) 95% CI
(1) XELOX 149.1 141.9–156.2 97.8 91.2–105.3
(2) FOLFOX 138.5 132.3–144.6 86.5 80.5–92.6
(1)–(2) 10.5 1.0–20.2 11.3 2.2–20.8
(c) Effectiveness (PFSD)
First-line therapy Second-line therapy
Chemotherapy regimen Estimated Effectiveness (PFSD) 95% CI Estimated Effectiveness (PFSD) 95% CI
(1) XELOX 253.4 241.2–265.9 165.8 153.9–178.3
(2) FOLFOX 262.7 251.0–274.6 163.6 152.2–175.6
(1)–(2)  9.3  26.7 to 7.6 2.2  14.4 to 19.2
CI¼confidence interval; LV¼leucovorin; PFSD¼progression-free survival days; QAPFSD¼quality-adjusted progression-free survival days.
Table 2 Utility scores for metastatic colorectal cancer
N Utility score 95% CI
(a) Chemotherapy
XELOX without adverse events 191 0.59 0.55–0.64
FOLFOX without adverse events 183 0.53 0.49–0.57
(b) Adverse events
Febrile neutropenia 175 0.39 0.36–0.42
Nausea/vomiting 192 0.38 0.35–0.42
Diarrhoea 188 0.42 0.39–0.45
Hand–foot syndrome 174 0.39 0.36–0.42
Fatigue 185 0.45 0.41–0.48
Peripheral neuropathy 176 0.45 0.41–0.48
Stomatitis 202 0.42 0.39–0.45
CI¼confidence interval.
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Because the FOLFOX4 regimen is currently administered to many
newly diagnosed MCRC patients, a comparison of cost-effectiveness
of XELOX and FOLFOX4 is important. Here, we showed that
first-line and second-line XELOX chemotherapy for MCRC was
‘dominant’ (i.e., showed better efficacy and resulted in lower
treatment costs), compared with FOLFOX4. These results were not
influenced by the sensitivity analysis. Our results are also
statistically robust because predicted values by linear or nonlinear
regression were not used.
Large sample size may have led to statistically significant
differences, but effect size was not very large. We are unsure of the
clinical significance of these differences, and it may therefore be
more appropriate to conclude that at minimum, XELOX produced
no fewer QALYs than did FOLFOX4. If the advantage of XELOX in
terms of personal preference is not taken into account, PFSD
values for XELOX and FOLFOX4 are not significantly different.
Given the non-inferiority of XELOX observed in both NO16966
and NO16967 trials, XELOX is superior in cost and non-inferior in
PFSD to FOLFOX4.
Very few data are available for an economic evaluation, which
compares oral chemotherapy with intravenous chemotherapy for
MCRC patients. In the United States, direct medical costs for
MCRC patients in the same NO16966 trial were estimated at US$
44500 for XELOX and US$ 45800 for FOLFOX4 (Garrison et al,
2007; Scheithauer et al, 2007; Chu and Cartwright, 2008). In the
United Kingdom, a cost-minimisation analysis showed the benefit
of oral chemotherapy by showing that treatment costs for a
12-week course of capecitabine (d2132) were lower than the costs
for the Mayo regimen (d3593), de Gramont regimen (d6255), and
modified de Gramont regimen (d3485) schedules over the same
treatment period (Ward et al, 2006). A Canadian study (Maroun
et al, 2003) reported similar findings in which oral uracil-tegafur
(UFT) regimen (UFT plus oral LV) saved 3221 Canadian dollars
per treatment compared with intravenous 5-FU plus oral LV. On
the basis of these results, oral chemotherapies result in lower costs
than intravenous therapies. This is consistent with our present
results.
Several limitations and strengths of our study should be noted.
Our analysis did not consider indirect costs, such as work loss
resulting from chemotherapy. Capecitabine plus oxaliplatin does
not require continuous infusion of 5-FU, and administration of
Table 4 Detailed mean costs per patient until progression of disease
Costs (h) of first-line chemotherapy Costs (h) of second-line chemotherapy
Chemotherapy regimen FOLFOX4 XELOX FOLFOX4 XELOX
Oxaliplatin 12200 11500 8800 8300
l-LV (branded) 3800 2600
l-LV (generic) 2700 1800
5-FU 600 400
Capecitabine — 3500 — 2300
Subtotal (1) Chemotherapy costs 16600 15000 11800 10600
Subtotal (1)’ Chemotherapy costs (involving generic l-LV) 15500 11000
5-HT3 antagonists 1050 600 800 410
Corticosteroids 70 40 50 30
Other medications 4 2 8 1
Subtotal (2) Pretreatment costs for chemotherapy 1100 600 900 440
Outpatient chemotherapy fee 1400 420 920 330
Blood test 750 750 420 420
Imaging diagnosis 1400 1400 750 830
Pharmacy fee 80 60
Subtotal (3) Outpatient chemotherapy costs 3600 2700 2100 1600
Subtotal (4) Medication costs for AEs 100 40 100 30
Total costs 21300 18300 14900 12600
Total costs (involving generic l-LV) 20200 14100
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Figure 2 The distribution of incremental effectiveness and cost. (A) first-
line therapy; (B) second-line therapy.
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sXELOX chemotherapy is less frequent than that of FOLFOX4. If we
include direct non-medical cost (such as costs of transportation of
patients to clinics) and indirect costs from the societal perspective,
incremental costs of XELOX would be even lower than the current
analysis from the payer’s perspective.
Although our study showed benefits of effectiveness of XELOX,
clinical trials proved that XELOX was non-inferior, rather than
superior, to FOLFOX4. This is mainly because a preference study
showed that general people preferred oral capecitabine, rather than
intravenous, chemotherapy. We think this is a reasonable result.
Moreover, the profile of grade 3/4 AEs was not different, except
that hand–foot syndrome occurred more frequently in the XELOX
group. However, utility scores were measured by Web-based
survey, and respondents were sampled from Internet panels, rather
than by random sampling from the population. Although we
recruited respondents stratified by age and gender, it is possible
that the characteristics of respondents or responses to the
questions were different than from a survey conducted among
the general population. This is also a limitation of this study.
We believe that XELOX effectiveness does not vary significantly
between Japanese and Euro-American patients. In the field of
oncology, recent methods of chemotherapy administration are
universally adopted. This is especially true for clinical trials in
which treatment methods such as chemotherapy regimen or
diagnostic imaging frequency are standardised by the protocols.
Therefore, a difference in resource use is also unlikely. The dose of
anticancer drugs administered, however, are lower in Japan, due to
the smaller body surface area of patients. Sensitivity analysis on
the dose of anticancer drugs showed that incremental costs were
lower if dose was reduced. The difference in costs between XELOX
and FOLFOX4 may expand in the Japanese setting. Furthermore,
the lack of a comparison with other oral chemotherapy drugs, such
as (UFT) or tegafur-gimestat-otastat potassium (TS-1), which are
widely used in Japan, is another limitation of our study.
According to our analysis, first-line and second-line use of
XELOX chemotherapy was superior to FOLFOX4 in terms of
effectiveness and costs. Although FOLFOX is a standard regimen
for MCRC patients, we recommend the use of the XELOX regimen
as a treatment option for MCRC patients.
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